Crizanlizumab: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes Recovery RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)−29%

Mortality (1)−33%

RCTs (2)−29%

Late (2)−29%

00.511.5+

← Crizanlizumab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Crizanlizumab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Leucker (DB RCT)68%0.32 · 0.01–7.49progression0/221/20CRITICAL Solomon (RCT)−33%1.33 · 0.85–2.21death37/21127/210ACTIV-4a

Late treatment−29%1.29 · 0.82–2.0337/23328/23029% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.27

All studies−29%1.29 · 0.82–2.0337/23328/23029% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2700.511.52+

Rotate screen for more detailsIncrease width for more details

← Crizanlizumab
reduces riskCrizanlizumab
increases risk →

c19early.org

October 2026

Crizanlizumab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Solomon (RCT)−33%1.33 · 0.85–2.2137/21127/210ACTIV-4a

Late treatment−33%1.33 · 0.84–2.1037/21127/21033% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.22

All studies−33%1.33 · 0.84–2.1037/21127/21033% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2200.511.52+

Rotate screen for more detailsIncrease width for more details

← Crizanlizumab
reduces riskCrizanlizumab
increases risk →

c19early.org

October 2026

Crizanlizumab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Leucker (DB RCT)68%0.32 · 0.01–7.49progression0/221/20CRITICAL Solomon (RCT)−33%1.33 · 0.85–2.21death37/21127/210ACTIV-4a

Late treatment−29%1.29 · 0.82–2.0337/23328/23029% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.27

All studies−29%1.29 · 0.82–2.0337/23328/23029% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2700.511.52+

Rotate screen for more detailsIncrease width for more details

← Crizanlizumab
reduces riskCrizanlizumab
increases risk →

c19early.org

October 2026

Crizanlizumab COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Leucker (DB RCT)−35%1.35 · 0.89–2.06no disch.22 (n)20 (n)CRITICAL

Late treatment−35%1.35 · 0.89–2.0622 (n)20 (n)35% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.16

All studies−35%1.35 · 0.89–2.0622 (n)20 (n)35% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1600.511.52+

Rotate screen for more detailsIncrease width for more details

← Crizanlizumab
reduces riskCrizanlizumab
increases risk →

c19early.org

October 2026

Crizanlizumab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Leucker (DB RCT)68%0.32 · 0.01–7.49progression0/221/20CRITICAL Solomon (RCT)−33%1.33 · 0.85–2.21death37/21127/210ACTIV-4a

Late treatment−29%1.29 · 0.82–2.0337/23328/23029% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.27

All studies−29%1.29 · 0.82–2.0337/23328/23029% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2700.511.52+

Rotate screen for more detailsIncrease width for more details

← Crizanlizumab
reduces riskCrizanlizumab
increases risk →

c19early.org

October 2026

Crizanlizumab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Solomon (RCT)−33%1.33 · 0.85–2.2137/21127/210ACTIV-4a

Late treatment−33%1.33 · 0.84–2.1037/21127/21033% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.22

All studies−33%1.33 · 0.84–2.1037/21127/21033% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2200.511.52+

Rotate screen for more detailsIncrease width for more details

← Crizanlizumab
reduces riskCrizanlizumab
increases risk →

c19early.org

October 2026

Crizanlizumab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Leucker (DB RCT)68%0.32 · 0.01–7.49progression0/221/20CRITICAL Solomon (RCT)−33%1.33 · 0.85–2.21death37/21127/210ACTIV-4a

Late treatment−29%1.29 · 0.82–2.0337/23328/23029% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.27

All studies−29%1.29 · 0.82–2.0337/23328/23029% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2700.511.52+

Rotate screen for more detailsIncrease width for more details

← Crizanlizumab
reduces riskCrizanlizumab
increases risk →

c19early.org

October 2026

Crizanlizumab COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Leucker (DB RCT)68%0.32 · 0.01–7.49progression0/221/20CRITICAL Leucker (DB RCT)9%0.91 · 0.06–13.59progression1/221/20CRITICAL Leucker (DB RCT)−35%1.35 · 0.89–2.06no disch.22 (n)20 (n)CRITICAL Solomon (RCT)−33%1.33 · 0.85–2.21death37/21127/210ACTIV-4a Solomon (RCT)−78%1.78 · 0.93–3.24death25/21114/210ACTIV-4a Solomon (RCT)−43%1.43 · 0.86–2.33misc.211 (n)210 (n)ACTIV-4a

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Crizanlizumab
reduces riskCrizanlizumab
increases risk →